The role of lebrikizumab in the treatment of atopic dermatitis in the adult population.

Article Details

Citation
Copy to clipboard

Prajapati S, Fardos M, Desai AD, Feldman SR

The role of lebrikizumab in the treatment of atopic dermatitis in the adult population.

Immunotherapy. 2023 Sep;15(13):981-991. doi: 10.2217/imt-2023-0066. Epub 2023 Jul 4.

PubMed ID
37401345 [ View in PubMed
]
Abstract

Although there are many atopic dermatitis (AD) treatments, finding a long-term medication with minimal side effects can be difficult. This review characterizes lebrikizumab as AD treatment in adults. A literature search was conducted to examine lebrikizumab's role in treating moderate to severe AD. In a phase III trial, 74% of adults with AD treated with lebrikizumab 250 mg every 4 weeks achieved an Investigator Global Assessment of 0/1, 79% achieved Eczema Area and Severity Index 75 and 79% experienced improvements in pruritus numeric rating scale scores relative to placebo. Common adverse effects in the ADvocate1 and ADvocate2 trials were conjunctivitis (7 and 8%, respectively), nasopharyngitis (4 and 5%, respectively) and headache (3 and 5%, respectively). Results from clinical trials suggest that lebrikizumab may be a viable alternative for AD management.

DrugBank Data that Cites this Article

Drugs